Novanta Inc at JPMorgan Healthcare Conference Transcript
Good afternoon. My name is Raji Gunasekera. I'm an associate on the healthcare team at JPMorgan. I'm pleased to introduce the CEO of Novanta, Matthijs Glastra with me here today. Thank you.
Thank you. Good afternoon, everybody. It's great to be at the JPMorgan Healthcare Conference again. I will start with providing an overview in the presentation of Novanta and our strategy in high-growth markets. And then Robert Buckley, who's here with me, our CFO, will join me for a Q&A session.
Before I get into the meat of the presentation, I just wanted to turn your attention into our safe harbor statement. I will be making some forward-looking statements as well as refer to non-GAAP financial measures, and you can see the details of the reconsolidation (sic) [reconciliation] of our GAAP to non-GAAP financial measures on our website.
So moving on to Slide #3, the Novanta overview at a glance. We're about an $850 million revenue company, a technology provider of what we call
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |